{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:08Z","timestamp":1794047408467,"version":"4.8.0"},"reference-count":47,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>PI3K\u03b4 inhibitors are active in patients with lymphoid neoplasms and a first series of them have been approved for the treatment of multiple types of B-cell lymphoid tumors, including marginal zone lymphoma (MZL). The identification of the mechanisms underlying either primary or secondary resistance is fundamental to optimize the use of novel drugs. Here we present a model of secondary resistance to PI3K\u03b4 inhibitors obtained by prolonged exposure of a splenic MZL cell line to idelalisib. The VL51 cell line was kept under continuous exposure to idelalisib. The study included detailed characterization of the model, pharmacological screens, silencing experiments, and validation experiments on multiple cell lines and on clinical specimens. VL51 developed resistance to idelalisib, copanlisib, duvelisib, and umbralisib. An integrative analysis of transcriptome and methylation data highlighted an enrichment of upregulated transcripts and low-methylated promoters in resistant cells, including IL-6\/STAT3- and PDGFRA-related genes and surface CD19 expression, alongside the repression of the let-7 family of miRNA, and miR-125, miR-130, miR-193 and miR-20. The IL-6R blocking antibody tocilizumab, the STAT3 inhibitor stattic, the LIN28 inhibitor LIN1632, the PDGFR inhibitor masitinib and the anti-CD19 antibody drug conjugate loncastuximab tesirine were active compounds in the resistant cells as single agents and\/or in combination with PI3K\u03b4 inhibition. Findings were validated on additional in vitro lymphoma models and on clinical specimens. A novel model of resistance obtained from splenic MZL allowed the identification of therapeutic approaches able to improve the antitumor activity of PI3K\u03b4 inhibitors in B-cell lymphoid tumors.<\/jats:p>","DOI":"10.3324\/haematol.2021.279957","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T02:58:03Z","timestamp":1651114683000},"page":"2685-2697","source":"Crossref","is-referenced-by-count":30,"title":["Resistance to PI3K\u03b4 inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6\/PDGFRA axis"],"prefix":"10.3324","volume":"107","author":[{"given":"Alberto J.","family":"Arribas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Cascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Barnabei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tarantelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afua Adjeiwaa","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Spriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Zucchetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Castro de Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Jovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bordone-Pittau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Di Veroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Cruciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Stussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"41394","doi-asserted-by":"crossref","unstructured":"Phillips TJ, Michot JM, Ribrag V. Can next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma?. Clin Lymphoma Myeloma Leuk. 2021; 21(1):8-20.","DOI":"10.1016\/j.clml.2020.08.022"},{"key":"41395","doi-asserted-by":"crossref","unstructured":"Kienle DL, Stilgenbauer S. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Opin Pharmacother. 2020; 21(8):917-929.","DOI":"10.1080\/14656566.2020.1737010"},{"key":"41396","doi-asserted-by":"crossref","unstructured":"Tarantelli C, Argnani L, Zinzani PL. PI3K\u03b4 inhibitors as immunomodulatory agents for the treatment of lymphoma patients. Cancers (Basel). 2021; 13(21):5535.","DOI":"10.3390\/cancers13215535"},{"key":"41397","doi-asserted-by":"crossref","unstructured":"Scheffold A, Jebaraj BMC, Tausch E. IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood. 2019; 134(6):534-547.","DOI":"10.1182\/blood.2018881029"},{"key":"41398","doi-asserted-by":"crossref","unstructured":"Chen L, Ouyang J, Wienand K. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor\/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica. 2020; 105(5):1361-1368.","DOI":"10.3324\/haematol.2019.216218"},{"key":"41399","doi-asserted-by":"crossref","unstructured":"Kim JH, Kim WS, Ryu KJ. CXCR4 can induce PI3K\u03b4 inhibitor resistance in ABC DLBCL. Blood Cancer J. 2018; 8(2):23.","DOI":"10.1038\/s41408-018-0056-9"},{"key":"41400","doi-asserted-by":"crossref","unstructured":"Faia K, White K, Murphy E. The phosphoinositide-3 kinase (PI3K)-\u03b4,\u03b3 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. PLoS One. 2018; 13(8):e0200725.","DOI":"10.1371\/journal.pone.0200725"},{"key":"41401","doi-asserted-by":"crossref","unstructured":"Yahiaoui A, Meadows SA, Sorensen RA. PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO\/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors. PLoS One. 2017; 12(2):e0171221.","DOI":"10.1371\/journal.pone.0171221"},{"key":"41402","doi-asserted-by":"crossref","unstructured":"Iyengar S, Clear A, Bodor C. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013; 121(12):2274-2284.","DOI":"10.1182\/blood-2012-10-460832"},{"key":"41403","doi-asserted-by":"crossref","unstructured":"Murali I, Kasar S, Naeem A. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood. 2021; 138(1):44-56.","DOI":"10.1182\/blood.2020006765"},{"key":"41404","unstructured":"Matera E-L, Fouret J, Baulu E. Enhanced sensitivity of idelalisib and ibrutinib-resistant cell lines to anti-CD38 antibodies. J Cancer Sci Clin Ther. 2020; 4:71-77."},{"key":"41405","doi-asserted-by":"crossref","unstructured":"Spriano F, Chung EYL, Gaudio E. The ETS inhibitors YK-4-279 and TK-216 are novel antilymphoma agents. Clin Cancer Res. 2019; 25(16):5167-5176.","DOI":"10.1158\/1078-0432.CCR-18-2718"},{"key":"41406","doi-asserted-by":"crossref","unstructured":"Hoellein A, Decker T, Bogner C. Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. J Cancer Res Clin Oncol. 2010; 136(3):403-410.","DOI":"10.1007\/s00432-009-0670-9"},{"key":"41407","doi-asserted-by":"crossref","unstructured":"Gaudio E, Tarantelli C, Spriano F. Targeting CD205 with the antibody drug conjugate MEN1309\/OBT076 is an active new therapeutic strategy in lymphoma models. Haematologica. 2020; 105(11):2584-2591.","DOI":"10.3324\/haematol.2019.227215"},{"key":"41408","doi-asserted-by":"crossref","unstructured":"Piva R, Deaglio S, Fama R. The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia. 2015; 29(2):503-507.","DOI":"10.1038\/leu.2014.294"},{"key":"41409","doi-asserted-by":"crossref","unstructured":"Arribas AJ, Rinaldi A, Mensah AA. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood. 2015; 125(12):1922-1931.","DOI":"10.1182\/blood-2014-08-596247"},{"key":"41410","doi-asserted-by":"crossref","unstructured":"Rossi D, Deaglio S, Dominguez-Sola D. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood. 2011; 118(18):4930-4934.","DOI":"10.1182\/blood-2011-06-359166"},{"key":"41411","doi-asserted-by":"crossref","unstructured":"Rossi D, Trifonov V, Fangazio M. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012; 209(9):1537-1551.","DOI":"10.1084\/jem.20120904"},{"key":"41412","doi-asserted-by":"crossref","unstructured":"Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell. 2009; 139(4):693-706.","DOI":"10.1016\/j.cell.2009.10.014"},{"key":"41413","doi-asserted-by":"crossref","unstructured":"Li D, Kong C, Tsun A. MiR-125a-5p decreases the sensitivity of Treg cells toward IL-6-mediated conversion by inhibiting IL-6R and STAT3 expression. Sci Rep. 2015; 5:14615.","DOI":"10.1038\/srep14615"},{"key":"41414","doi-asserted-by":"crossref","unstructured":"Singh BN, Kawakami Y, Akiyama R. The Etv2-miR-130a network regulates mesodermal specification. Cell Rep. 2015; 13(5):915-923.","DOI":"10.1016\/j.celrep.2015.09.060"},{"key":"41415","doi-asserted-by":"crossref","unstructured":"Mazzu YZ, Hu Y, Shen Y. miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFbeta, and Wnt signaling. Sci Rep. 2019; 9(1):3197.","DOI":"10.1038\/s41598-019-39560-0"},{"key":"41416","doi-asserted-by":"crossref","unstructured":"Slattery ML, Mullany LE, Sakoda LC. The MAPK-signaling pathway in colorectal cancer: dysregulated genes and their association with microRNAs. Cancer Inform. 2018; 17:1176935118766522.","DOI":"10.1177\/1176935118766522"},{"key":"41417","unstructured":"Actemra (tocilizumab): highlights of prescribing information. 2021. Publisher Full Text|"},{"key":"41418","unstructured":"Zynlonta (loncastuximab tesirine): highlights of prescribing information. 2021. Publisher Full Text|"},{"key":"41419","doi-asserted-by":"crossref","unstructured":"Tarantelli C, Gaudio E, Arribas AJ. PQR309 is a novel dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. 2018; 24(1):120-129.","DOI":"10.1158\/1078-0432.CCR-17-1041"},{"key":"41420","doi-asserted-by":"crossref","unstructured":"Arribas AJ, Campos-Mart\u00edn Y, G\u00f3mez-Abad C. Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood. 2012; 119(3):e9-e21.","DOI":"10.1182\/blood-2011-02-339556"},{"key":"41421","doi-asserted-by":"crossref","unstructured":"Arribas AJ, Gomez-Abad C, Sanchez-Beato M. Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Mod Pathol. 2013; 26(7):889-901.","DOI":"10.1038\/modpathol.2012.220"},{"key":"41422","doi-asserted-by":"crossref","unstructured":"Lenz G, Wright G, Dave SS. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-2323.","DOI":"10.1056\/NEJMoa0802885"},{"key":"41423","unstructured":"Wu D, Yan Y, Wei T. A targetable epigenetic vulnerability in PI3K\/AKT inhibitor resistant cancers. bioRxiv.Publisher Full Text|"},{"key":"41424","doi-asserted-by":"crossref","unstructured":"Quagliano A, Gopalakrishnapillai A, Barwe SP. Understanding the mechanisms by which epigenetic modifiers avert therapy resistance in cancer. Front Oncol. 2020; 10:992.","DOI":"10.3389\/fonc.2020.00992"},{"key":"41425","doi-asserted-by":"crossref","unstructured":"Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A. Role of DNA methylation in the resistance to therapy in solid tumors. Front Oncol. 2020; 10:1152.","DOI":"10.3389\/fonc.2020.01152"},{"key":"41426","doi-asserted-by":"crossref","unstructured":"Garcia-Martinez L, Zhang Y, Nakata Y. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021; 12(1):1786.","DOI":"10.1038\/s41467-021-22024-3"},{"key":"41427","doi-asserted-by":"crossref","unstructured":"Wright SCE, Vasilevski N, Serra V. Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity. Cancers (Basel). 2021; 13(7):1538.","DOI":"10.3390\/cancers13071538"},{"key":"41428","doi-asserted-by":"crossref","unstructured":"Kim JH, Kim WS, Park C. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma. BMC Cancer. 2019; 19(1):936.","DOI":"10.1186\/s12885-019-6057-7"},{"key":"41429","doi-asserted-by":"crossref","unstructured":"Yun MR, Choi HM, Kang HN. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Oncogene. 2018; 37(3):377-388.","DOI":"10.1038\/onc.2017.339"},{"key":"41430","doi-asserted-by":"crossref","unstructured":"Bonfiglio F, Bruscaggin A, Guidetti F. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022; 139(5):732-747.","DOI":"10.1182\/blood.2021014198"},{"key":"41431","doi-asserted-by":"crossref","unstructured":"Kumari N, Dwarakanath BS, Das A. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016; 37(9):11553-11572.","DOI":"10.1007\/s13277-016-5098-7"},{"key":"41432","doi-asserted-by":"crossref","unstructured":"Chen JG, Liu X, Munshi M. BTK Cys481Ser drives ibrutinib resistance via ERK1\/2 and protects BTK wild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018; 131(18):2047-2059.","DOI":"10.1182\/blood-2017-10-811752"},{"key":"41433","doi-asserted-by":"crossref","unstructured":"Piskounova E, Polytarchou C, Thornton JE. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 2011; 147(5):1066-1079.","DOI":"10.1016\/j.cell.2011.10.039"},{"key":"41434","doi-asserted-by":"crossref","unstructured":"Chen J, Ouyang H, An X. miR-125a is upregulated in cancer stem-like cells derived from TW01 and is responsible for maintaining stemness by inhibiting p53. Oncol Lett. 2019; 17(1):87-94.","DOI":"10.3892\/ol.2018.9587"},{"key":"41435","doi-asserted-by":"crossref","unstructured":"Verhaak RG, Hoadley KA, Purdom E. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110.","DOI":"10.1016\/j.ccr.2009.12.020"},{"key":"41436","doi-asserted-by":"crossref","unstructured":"Ip CKM, Ng PKS, Jeong KJ. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nat Commun. 2018; 9(1):4583.","DOI":"10.1038\/s41467-018-06949-w"},{"key":"41437","doi-asserted-by":"crossref","unstructured":"Li GZ, Raut CP. Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies. Onco Targets Ther. 2019; 12:5123-5133.","DOI":"10.2147\/OTT.S180763"},{"key":"41438","doi-asserted-by":"crossref","unstructured":"Lim SE, Esain V, Kwan W. HIF1\u03b1-induced PDGFR\u03b2 signaling promotes developmental HSC production via IL-6 activation. Exp Hematol. 2017; 46:83-95.e6.","DOI":"10.1016\/j.exphem.2016.10.002"},{"key":"41439","doi-asserted-by":"crossref","unstructured":"Bernat-Peguera A, Sim\u00f3n-Extremera P, da Silva-Diz V. PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma. Oncogene. 2019; 38(25):5021-5037.","DOI":"10.1038\/s41388-019-0773-y"},{"key":"41440","doi-asserted-by":"crossref","unstructured":"Laforgia M, Marech I, Nardulli P. An evaluation of masitinib for treating systemic mastocytosis. Expert Opin Pharmacother. 2019; 20(13):1539-1550.","DOI":"10.1080\/14656566.2019.1645121"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279957\/74417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279957\/74985","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10617\/74417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:36Z","timestamp":1794045696000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279957","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,28]]}}}